Cellectar Biosciences, Inc. (CLRB)
1.25
+0.10
(+8.70%)
USD |
NASDAQ |
Nov 06, 16:00
1.24
-0.01
(-0.80%)
After-Hours: 20:00
Cellectar Biosciences Enterprise Value : -22.15M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | -22.15M |
| November 05, 2026 | -22.97M |
| November 04, 2026 | -22.31M |
| November 03, 2026 | -21.65M |
| November 02, 2026 | -22.39M |
| October 30, 2026 | -22.52M |
| October 29, 2026 | -22.39M |
| October 28, 2026 | -22.23M |
| October 27, 2026 | -22.48M |
| October 26, 2026 | -22.48M |
| October 23, 2026 | -22.39M |
| October 22, 2026 | -22.81M |
| October 21, 2026 | -21.90M |
| October 20, 2026 | -22.31M |
| October 19, 2026 | -23.22M |
| October 16, 2026 | -23.06M |
| October 15, 2026 | -22.64M |
| October 14, 2026 | -22.72M |
| October 13, 2026 | -20.99M |
| October 12, 2026 | -20.66M |
| October 09, 2026 | -20.50M |
| October 08, 2026 | -20.91M |
| October 07, 2026 | -20.00M |
| October 06, 2026 | -20.00M |
| October 05, 2026 | -18.68M |
| Date | Value |
|---|---|
| October 02, 2026 | -17.77M |
| October 01, 2026 | -17.03M |
| September 30, 2026 | -17.28M |
| September 29, 2026 | -17.44M |
| September 28, 2026 | -17.36M |
| September 25, 2026 | -17.61M |
| September 24, 2026 | -15.34M |
| September 23, 2026 | -15.22M |
| September 22, 2026 | -14.06M |
| September 21, 2026 | -13.07M |
| September 18, 2026 | -12.82M |
| September 17, 2026 | -12.66M |
| September 16, 2026 | -13.07M |
| September 15, 2026 | -13.32M |
| September 14, 2026 | -13.40M |
| September 11, 2026 | -13.40M |
| September 10, 2026 | -12.90M |
| September 09, 2026 | -12.95M |
| September 08, 2026 | -12.57M |
| September 04, 2026 | -12.90M |
| September 03, 2026 | -13.07M |
| September 02, 2026 | -12.41M |
| September 01, 2026 | -12.16M |
| August 31, 2026 | -11.75M |
| August 28, 2026 | -11.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.764B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
| Anika Therapeutics, Inc. | 176.07M |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 2.710B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.931M |
| Total Expenses (Quarterly) | 6.931M |
| EPS Diluted (Quarterly) | -0.5666 |
| Earnings Yield | -364.3% |
| Normalized Earnings Yield | -375.10 |